株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

EpiCast Report:末梢動脈疾患 (PAD) の疫学的予測 (2024年まで)

EpiCast Report: Peripheral Arterial Disease - Epidemiology Forecast to 2024

発行 GlobalData 商品コード 344636
出版日 ページ情報 英文 72 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
EpiCast Report:末梢動脈疾患 (PAD) の疫学的予測 (2024年まで) EpiCast Report: Peripheral Arterial Disease - Epidemiology Forecast to 2024
出版日: 2015年10月06日 ページ情報: 英文 72 Pages
概要

末梢動脈疾患 (PAD) とは、動脈、特に冠状動脈や頭蓋内血管の血流が妨害された結果生じる疾患ですが、頭蓋外頸動脈循環・上肢動脈で発症する場合もあります。ただし、PAD研究の中心は、脚部動脈における (主にアテローム硬化症が原因の) 慢性の動脈閉塞性疾患に置かれています。PADはその重症度に基づいて (Fontainの分類法に従い)、ステージI〜IVにまで分類されます。世界8ヶ国におけるPADの有病者数は、2014年には66,433,407人、2024年には94,490,894人と、年間平均4.22%もの速度で増加しています。また、受診済みの有病者数は、2014年には7,900,097人、2024年には10,797,78と、年間平均3.67%で増加しています。

当レポートでは、世界の主要8ヶ国 (米国、ドイツ、フランス、イタリア、スペイン、英国、日本、中国 (都市部)) における末梢動脈疾患 (以下PAD) の発症状況と今後の見通しについて分析し、疾患の特徴や、現在の有病者の発症状況、今後10年間の有病件数の予測値などを調査・推計しております。

第1章 目次

第2章 イントロダクション

  • 疾患の概略
  • 関連分析
  • 刊行予定の関連分析

第3章 疾患の背景事情

  • リスク要因と共存症
  • 世界的な傾向
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法
  • PADの有病者数の疫学的予測 (今後11年間分)
    • 有病者総数
    • 年齢別の有病者数
    • 男女別の有病者数
    • 有病者数 (年齢調整済み)
    • 症候性/無症候性PADの有病者数
    • PAD有病者のうち、間欠跛行・重症虚血肢を併発している人数
    • PAD有病者のうち、症候性/無症候性PAD・間欠跛行・重症虚血肢を伴う者の比率
    • PAD有病者のうち、高血圧・糖尿病を併発している人数
  • PADの有病者のうち、診断を受診した人数の疫学的予測 (今後11年間分)
    • 受診済みの有病者総数
    • 年齢別の受診済み有病者数
    • 男女別の受診済み有病者数
    • 受診済み有病者数 (年齢調整済み)
    • 受診済みの症候性/無症候性PADの有病者数
    • 受診済みPAD有病者のうち、間欠跛行・重症虚血肢を併発している人数
    • 受診済みPAD有病者のうち、症候性/無症候性PAD・間欠跛行・重症虚血肢を伴う者の比率
    • 受診済みPAD有病者のうち、高血圧・糖尿病を併発している人数
  • 議論
    • 疫学的予測に関する考察
    • 分析の限界
    • 分析の強み

第4章 付録

図表一覧

目次
Product Code: GDHCER090-15

Peripheral artery disease (PAD) refers to conditions that result in the obstruction of blood flow in the arteries, predominantly in the coronary and intercranial vessels, and may also refer to complications with the extracranial carotid circulation and the upper extremity arteries. However, the general focus of PAD research is on chronic arterial occlusive disease of the arteries in the legs, primarily caused by atherosclerosis. PAD is typically divided into four clinical stages with increasing degrees of severity: Stage I, Stage II, Stage III, and Stage IV based on the Fontaine classification.

GlobalData epidemiologists forecast an increase in the total prevalent cases of PAD in the 8MM, from 66,433,407 in 2014 to 94,490,894 cases in 2024 with an annual growth rate (AGR) of 4.22%. Additionally the number of diagnosed incident cases of PAD is expected to grow from 7,900,097 cases in 2014 to 10,797,781 cases in 2024 at an AGR of 3.67%.

GlobalData epidemiologists used comprehensive country-specific data from population-based studies, which were published in peer-reviewed journal articles, to arrive at a meaningful, in-depth analysis and forecast for the total and diagnosed prevalent cases of PAD, asymptomatic and symptomatic cases of PAD, PAD cases with IC, cases of PAD with CLI, cases of PAD with comorbid hypertension, and cases of PAD with comorbid diabetes. Additionally, sex- and age-specific segmentation for the total prevalent cases and the diagnosed prevalent cases of PAD was obtained. Furthermore, GlobalData epidemiologists ensured that all the studies used to obtain the data regarding the total prevalence of PAD across the 8MM used the gold standard diagnosis definition, where patients are only considered to have PAD if they have an ABPI less than or equal to 0.9, thereby allowing for meaningful comparisons of the segmentation populations across the 8MM.

Scope

  • The Peripheral Arterial Disease (PAD) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for PAD in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Urban China). It includes a 10-year epidemiological forecast of the total and diagnosed prevalent cases of PAD segmented by sex and age (beginning at 35 years and ending at =85 years) in these markets. Additionally, both the total and diagnosed prevalent cases of PAD are further segmented in symptomatic PAD, asymptomatic PAD, PAD with intermittent claudication (IC), PAD with critical limb ischemia (CLI), PAD with hypertension, and PAD with diabetes.
  • The PAD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The PAD EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global PAD market.
  • Quantify patient populations in the global PAD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for PAD therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Background

  • 3.1. Risk Factors and Comorbidities
  • 3.2. Global Trends
  • 3.3. Forecast Methodology
    • 3.3.1. Sources Used
    • 3.3.2. Sources Not Used
    • 3.3.3. Forecast Assumptions and Methods
  • 3.4. Epidemiological Forecast of Total Prevalent Cases of PAD (2014-2024)
    • 3.4.1. Total Prevalent Cases of PAD
    • 3.4.2. Age-Specific Total Prevalent Cases of PAD
    • 3.4.3. Sex-Specific Total Prevalent Cases of PAD
    • 3.4.4. Age-Adjusted Total Prevalence of PAD
    • 3.4.5. Total Prevalent Asymptomatic and Symptomatic Cases of PAD
    • 3.4.6. Total Prevalent Cases of PAD with Intermittent Claudication and PAD with Critical Limb Ischemia
    • 3.4.7. Proportion of Total PAD Cases that Present as Asymptomatic, PAD with Intermittent Claudication, and PAD with Critical Limb Ischemia
    • 3.4.8. Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes
  • 3.5. Epidemiological Forecast of Diagnosed Prevalent Cases of PAD (2014-2024)
    • 3.5.1. Diagnosed Prevalent Cases of PAD
    • 3.5.2. Age-Specific Diagnosed Prevalent Cases of PAD
    • 3.5.3. Sex-Specific Diagnosed Prevalent Cases of PAD
    • 3.5.4. Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD
    • 3.5.5. Diagnosed Prevalent Cases of PAD with Intermittent Claudication and PAD with Critical Limb Ischemia
    • 3.5.6. Proportion of Diagnosed PAD Cases that Present as Symptomatic, PAD with Intermittent Claudication, and PAD with Critical Limb Ischemia
    • 3.5.7. Diagnosed Prevalent Cases of PAD with Hypertension and PAD Cases with Diabetes
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. Primary Research - Prescriber Survey
  • 4.3. About the Authors
    • 4.3.1. Epidemiologists
    • 4.3.2. Reviewers
    • 4.3.3. Global Director of Therapy Analysis and Epidemiology
    • 4.3.4. Global Head of Healthcare
  • 4.4. About GlobalData
  • 4.5. About EpiCast
  • 4.6. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for PAD
  • Table 2: 8MM, Sources of Epidemiological Data Used to Forecast the Total Prevalent Cases of PAD
  • Table 3: 8MM, Sources of Epidemiological Data Used to Forecast Symptomatic and Asymptomatic Total Prevalent Cases of PAD
  • Table 4: 8MM, Sources of Epidemiological Data Used to Forecast the IC and CLI Total Prevalent Cases of PAD
  • Table 5: 8MM, Sources of Epidemiological Data Used to Forecast Total Prevalent Cases of PAD with Hypertension or Diabetes
  • Table 6: 8MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of PAD
  • Table 7: 8MM, Sources of Epidemiological Data Used to Forecast Asymptomatic and Symptomatic Diagnosed Prevalent Cases of PAD
  • Table 8: 8MM, Sources of Epidemiological Data Used for the Forecast of the Proportion of the Diagnosed PAD Population that Presents with IC
  • Table 9: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of PAD with Hypertension or Diabetes
  • Table 10: 8MM, Total Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024
  • Table 11: 8MM, Age-Specific Total Prevalent Cases of PAD, Both Sexes, N (Row %), 2014
  • Table 12: 8MM, Sex-Specific Total Prevalent Cases of PAD, Ages ≥35 Years, N (Row %), 2014
  • Table 13: 8MM, Total Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N (Row %), 2014
  • Table 14: 8MM, Total Prevalent Cases of PAD with IC and PAD with CLI, Both Sexes, Ages ≥35 Years, N , 2014
  • Table 15: 8MM, Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N (Row %), 2014
  • Table 16: 8MM, Diagnosed Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024
  • Table 17: 8MM, Age-Specific Diagnosed Prevalent Cases of PAD, Both Sexes, N, 2014
  • Table 18: 8MM, Sex-Specific Diagnosed Prevalent Cases of PAD, Ages ≥35 Years, N (Row %), 2014
  • Table 19: 8MM, Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N (Row %), 2014
  • Table 20: 8MM, Diagnosed Prevalent Cases of PAD with IC or CLI, Both Sexes, Ages ≥35 Years, N, 2014
  • Table 21: 8MM, Diagnosed Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N (Row %), 2014
  • Table 22: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

  • Figure 1: 8MM, Patient Flow for the Epidemiological Forecast of PAD
  • Figure 2: 8MM, Total Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024
  • Figure 3: 8MM, Age-Specific Total Prevalent Cases of PAD, Both Sexes, N, 2014
  • Figure 4: 8MM, Sex-Specific Total Prevalent Cases of PAD, Ages ≥35 Years, N, 2014
  • Figure 5: 8MM, Age-Standardized Total Prevalence of PAD, 2014
  • Figure 6: 8MM, Total Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N, 2014
  • Figure 7: 8MM, Total Prevalent Cases of PAD with IC and PAD with CLI, Both Sexes, Ages ≥35 Years, N, 2014
  • Figure 8: 8MM, Proportion of Total PAD Cases that Present as Asymptomatic, PAD with IC, and PAD with CLI, Both Sexes, Ages ≥35 Years, %
  • Figure 9: 8MM, Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N, 2014
  • Figure 10: 8MM, Diagnosed Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024
  • Figure 11: 8MM, Age-Specific Diagnosed Prevalent Cases of PAD, Both Sexes, N, 2014
  • Figure 12: 8MM, Sex-Specific Diagnosed Prevalent Cases of PAD, Ages ≥35 Years, N, 2014
  • Figure 13: 8MM, Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N, 2014
  • Figure 14: 8MM, Diagnosed Prevalent Cases of PAD with IC or CLI, Both Sexes, Ages ≥35 Years, N, 2014
  • Figure 15: 8MM, Proportion of Diagnosed PAD Cases that Present as Asymptomatic, PAD with IC, and PAD with CLI, Both Sexes, Ages ≥35 Years, %, 2014
  • Figure 16: 8MM, Diagnosed Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N, 2014
Back to Top